In addition, Zhou [36] found that the ORR in Chinese NSCLC patients with RET mutation who deal with Pralsetinib were 66.7% and 83.3% in previously treated group and untreated group, respectively. The gene discussed is RET; the disease is non-small cell lung carcinoma.